EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Rho GTPases in cancer resistance: mechanisms, vulnerabilities, and therapeutic opportunities

Amy Beaudin, Philippe Lefrançois, Mélanie Laurin iD

Biochemical Society Transactions · 2026

DOI: 10.1042/bst20250097 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochemical Society Transactions, 2026. Verfasst von Amy Beaudin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Département de biologie moléculaire, biochimie médicale et pathologie, Faculté de médecine, Université Laval, Québec, QC, Canada. Hauptthemen laut MEDLINE: Neoplasms, rho GTP-Binding Proteins, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research Society (CRS).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intrinsic and adaptive resistance to therapy remain major barriers to effective cancer treatment. Diverse resistance mechanisms, including epithelial-mesenchymal transition, enhanced tolerance to DNA damage, impaired cell death pathways, metabolic reprogramming, and cues from the tumour microenvironment, are increasingly recognised as being tightly integrated with Rho GTPase signalling networks. Accumulating evidence positions these pathways as central regulators of therapeutic resistance across multiple cancer types. In this review, we synthesise recent experimental findings linking Rho GTPase-mediated signalling to therapy resistance and evaluate emerging strategies aimed at targeting these signalling axes. We critically examine the translational readiness of approaches that directly inhibit Rho GTPases, disrupt downstream effector pathways, or modulate canonical regulators such as RhoGEFs and RhoGAPs, and discuss the key challenges and opportunities associated with their clinical deployment. Collectively, these insights highlight the therapeutic potential of targeting Rho GTPase signalling as a foundation for next-generation cancer treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasmsrho GTP-Binding ProteinsDrug Resistance, NeoplasmHumansSignal TransductionAnimalsEpithelial-Mesenchymal TransitionTumor MicroenvironmentAntineoplastic Agents

Stichwörter der Autor:innen

Rho GTPasecancerchemotherapy resistancesignallingsmall moleculestreatment resistance

Substanzen

rho GTP-Binding ProteinsAntineoplastic Agents

Autor:innen und Institutionen

  • Département de biologie moléculaire, biochimie médicale et pathologie, Faculté de médecine, Université Laval, Québec, QC, Canada.
  • Oncology Research program, CHU de Québec - Université Laval Research Center, Québec, QC, Canada.
  • Centre de recherche sur le cancer de l'Université Laval (CRC), Québec, QC, Canada.
  • Centre de recherche en organogénèse expérimentale (LOEX), Québec, QC, Canada.
  • Cancer Axis, Lady Davis Institute for Medical Research, Montreal, QC, Canada.
  • Division of Experimental Medicine, McGill University, Montreal, QC, Canada.

ORCID-Profile: Mélanie Laurin

Förderung

  • Cancer Research Society (CRS)

Zitieren

APA

Beaudin, A., Lefrançois, P., & Laurin, M. (2026). Rho GTPases in cancer resistance: mechanisms, vulnerabilities, and therapeutic opportunities. Biochemical Society Transactions. https://doi.org/10.1042/bst20250097

Vancouver

Beaudin A, Lefrançois P, Laurin M. Rho GTPases in cancer resistance: mechanisms, vulnerabilities, and therapeutic opportunities. Biochemical Society Transactions. 2026. doi:10.1042/bst20250097

BibTeX
@article{Beaudin2026,
  author = {Beaudin, Amy and Lefrançois, Philippe and Laurin, Mélanie},
  title = {Rho GTPases in cancer resistance: mechanisms, vulnerabilities, and therapeutic opportunities},
  journal = {Biochemical Society Transactions},
  year = {2026},
  doi = {10.1042/bst20250097}
}
Kostenlos starten →